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Sero-epidemiology of measles-specific IgG antibodies and 
predictive factors for low or missing titres in a German 
population-based cross-sectional study in children and adolescents 
(KiGGS) 
 
Background and objective:  
In the European Region, measles elimination is now targeted to 2015. To measure progress 
towards elimination age-group specific susceptibility targets have been defined. Age-specific 
measles susceptibility in children and adolescents was evaluated in Germany. Taking into 
account a broad range of socio-demographic, health- and vaccination status related variables, 
populations for vaccination campaigns were identified. 
Method 
We analysed data from children aged 1 to 17 years in the representative German Health 
Interview and Examination Survey for Children and Adolescents (KiGGS). Measles 
immunoglobulin G antibodies were measured in 13,977 participants by enzyme immunoassay 
(ELISA). Bivariate and multivariate
 
logistic regression analyses were used to determine 
parental and infant related factors associated with measles susceptibility. 
Results 
The overall prevalence of seronegativity in children tested for measles IgG aged 1 to 17 years 
was 10.0% (95% CI 9.4-10.7). The prevalence of seronegativity in the German population was 
below the WHO targets for measles elimination in children aged 2 to 9 year-olds but exceeded 
the target for 10 to 17 year-olds. Age differences in the level of seronegativity were found to 
be mainly due to differences in vaccination coverage. A higher level of susceptibility was 
observed if parents did not comply with the request to present the child’s vaccination card. In 
vaccinated children, immigration, male gender, very young age at first vaccination and a 
longer time period since last vaccination were associated with a higher level of susceptibility. 
Conclusion 
Further increase of the two-dose vaccination coverage is necessary in order to achieve the 
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 37 
1. Introduction 38 
Measles, elimination goal: 39 
Despite worldwide vaccination activities, measles is still a major cause of death especially in 40 
young children. The WHO called into action a program that led to successful elimination in 41 
the Americas and a reduction in disease burden in Africa and Asia. Although Europe had 42 
targeted measles for elimination by the year 2010, this goal was not met and a new target date 43 
for eliminating measles has been set to 2015. Successful elimination will be accredited to the 44 
European region when the following criteria have been met: vaccine coverage of more than 45 
95%, continued disease surveillance with incidence rates below 1 per million population as 46 
well as a rate 80% laboratory confirmed suspected cases. In addition the WHO European 47 



































































the whole population should not exceed 15% in children aged 2-4 years, < 10% in 5- to 9-49 
year-olds and < 5% in older age groups (1). 50 
 51 
German situation: 52 
In Germany, indigenous measles circulation has been interrupted (2), but importation of 53 
measles virus (MV) from other countries is common (3). Pockets of susceptible individuals 54 
often associated with anthroposophic communities or the catchment area of a naturopathist 55 
have experienced MV transmission leading to small and middle-sized outbreaks (4-6). 56 
In Germany, a two-dose regime is recommended for measles mumps rubella (MMR) 57 
vaccination by the Standing Committee of Vaccination (STIKO). The first dose should be 58 
given at months 11-14, the second dose not less than 4 weeks later. MMR immunisation 59 
should be completed at the age of 2. Vaccination coverage in Germany has been described in 60 
our previous study (7). Besides several smaller outbreaks, a large measles outbreak occurred 61 
in North-Rhine Westphalia, Germany in 2006. Analysis of the age distribution revealed that 62 
the majority of cases were aged > 9 years (8, 9) and that also a high number of infants was 63 
affected. Investigation of a school outbreak in the city of Duisburg displayed major 64 
immunisation gaps in older children and young adults. These results indicate a need for 65 
further studies in German children, adolescents and young adults to assess the demand on 66 
supplementary immunisation activities. 67 
The German Health Interview and Examination Survey for Children and Adolescents 68 
(KiGGS) was conducted in a representative sample of children 0-17 years of age. Health 69 
related and socio-demographic data plus the vaccination status were recorded. A blood sample 70 
was obtained from children aged >1. This set-up enabled us for the first time to study the 71 
seroprevalence of measles-specific IgG antibodies in a well-defined cohort representative for 72 
all children in Germany. Moreover, titres could be correlated to the time point of vaccination 73 
and the number of doses administered. Analysing these data, we investigated presence of gaps 74 
in seroprevalence in certain age groups and identified factors predicting low measles IgG titre 75 
seroprevalence in vaccinated children. 76 
 77 
2. Methods 78 



































































The KiGGS methodology has been described elsewhere (10, 11). In brief, the KiGGS survey 80 
is based on a nationally representative sample of children and adolescents 0-17 years of age 81 
with main residence in Germany. A total of 17,641 children and adolescents were surveyed – 82 
8985 boys and 8656 girls. Study participants were enrolled from May 2003 to May 2006. 83 
Children and adolescents from families with a non-German nationality were oversampled, as a 84 
higher proportion of undeliverable contacts and non-respondents were expected in this 85 
subgroup as compared to children from non-migrant families. A migration-specific approach 86 
was used and, thus, it was possible to include children with a migration background according 87 
to their proportion in the general population. A total of 2,590 children and adolescents with a 88 
migration background (both parents) took part in the study (17%). Another 1,292 children and 89 
adolescents (8.3%) have one parent with a migration background.  90 
The overall response for eligible children and adolescents was 66.6% and showed little 91 
variation between age groups and sexes, but marked variation between children with and 92 
without migration background. Analyses of the short non-responder questionnaires revealed 93 
that the collected data give comprehensive and nationally representative evidence on the 94 
health status of children and adolescents aged 0 to 17 years.  95 
Questionnaires for children and a parent delivered data on medical history, socioeconomic 96 
status, and migration background. Data on vaccination was collected directly from the 97 
vaccination cards. The assigned maternal education levels relate to the German school system 98 
which provides three different types of secondary education.  99 
In children aged 1 to 17 years, parents and children were asked to consent to taking of a blood 100 
sample. In 13,977 (83.7%) study subjects, a blood sample could be taken and subsequently 101 
tested for the presence of measles IgG antibodies. Presented seroprevalence estimates are 102 
based on this group. In 13,017 (93.1%) of children who were tested for measles antibodies, 103 
information about vaccinations could be obtained from vaccination cards or parents reported 104 
that the children were unvaccinated. Participants with missing or incomplete information on 105 
vaccinations were excluded from any further analyses of determinants of seronegativity. 106 
2.2. Statistical Analysis 107 
Estimates of vaccination coverage
 
and their confidence intervals (CIs) were calculated using
 
108 
SPSS version 18 (SPSS Inc. Chicago, Illinois). In order to assure that estimates derived from 109 



































































throughout the statistical analyses. Analyses were performed using SPSS Complex Samples 111 
procedure and, thus, accounted for the stratified and clustered sample design of our survey. 112 
Calculations of the seroprevalence included all children with a known titre, regardless of the 113 
quality of their vaccination documentation. In a second step, the seroprevalence of measles 114 
antibodies was stratified by socio-demographic factors (sex, age, migration background, 115 
maternal education level) and factors related to vaccination status (number of vaccination 116 
doses, age at first measles vaccination, years since last measles vaccination, history of a 117 
measles infection). In these analyses only children were included for whom a vaccination card 118 
was presented or for whom it was reported that they were (still) unvaccinated. The association 119 
between seronegativity and different vaccination strategies (number of vaccination doses, age 120 
at first measles vaccination), factors known to be associated with measles titre (years since 121 
last measles vaccination, history of a measles infection) and factors which may be related to 122 
the quality of vaccination (vaccination abroad) or to the probability of natural measles 123 
infection and of its perception by parents (foreign born migrants, maternal education level) 124 
were analysed by uni- and multivariate regression analyses. These latter analyses were 125 
restricted to vaccinated children with valid vaccination documents. Children whose blood 126 
sample was taken within 21 days after their first vaccination (n=30) were excluded to avoid 127 
inclusion of children in the early immune response phase where antibodies may not be present 128 
and serology may therefore be false-negative. 129 
2.3 Laboratory methods 130 
Measles IgG ELISA.  131 
The Measles IgG titre of all serum samples was determined by the Siemens Enzygnost anti-132 
measles IgG test (Siemens, Marburg, Germany) using an automated processor (Tecan 133 
Evolyzer, Germany). All samples were tested with kits of the same lot number. The result of 134 
the ELISA was expressed quantitatively as an antibody concentration (mIU/ml) of optical 135 
density (OD) according to the manufacturer’s instructions. Samples were categorised as 136 
seropositive, equivocal or seronegative according to the cut-off values proposed by the 137 
manufacturer. Samples with equivocal samples were repeated once. Based on the widely 138 
agreed categories for IgG antibody negativity (IgG titre <150 mIU/ml), seropositivity (IgG 139 



































































obtained OD/IgG titre was categorised taking into account the respective manufacturers 141 
correction factors. 142 
Focus of infection reduction neutralisation test (FRNT).  143 
Compared to the ELISA measuring all classes of IgG able to bind to the respective antigen, 144 
the Focus Reduction Neutralisation Test (FRNT) and Plaque Reduction Neutralisation Test 145 
(PRNT) quantify only antibodies capable to prevent infection of cells. FRNT and PRNT are 146 
known to be more sensitive than ELISA. Recently FRNT was shown to be a good substitute 147 
for PRNT for characterising the immune response to mumps and for vaccine efficacy studies 148 
(12). Although the FRNT is less laborious than the PRNT, it cannot be used for large numbers 149 
of samples. Thus, the FRNT was used to characterise only the sera of patients tested negative 150 
in ELISA after vaccination in order to determine whether they had neutralising antibodies. 151 
The FRNT was performed as follows: Vero-SLAM cells were seeded in 48 well plates and 152 
incubated for 48 h. Serum samples were inactivated for 30 min at 56°C and serially diluted. 153 
Edmonston Zagreb (30 pfu in 50 µl) was incubated for 1 h at 37°C. Cells were inoculated 154 
with 100 µl of the serum/virus mixture for 1h at 37°C in a CO2 incubator and covered with a 155 
500 µl overlay of 1% carboxymethylcellulose (CMC). Cells were incubated for 5 d at 37°C 156 
and 5% CO2. For fixation, cells were washed with cold Phosphate buffered saline (PBS) and 157 
covered with 2% paraformaldehyd for 30 min on ice. Each well was washed with PBS and 158 
treated for 10 min with 200 µl methanol at -20°C. After a third wash with PBS, 200 µl of 159 
blocking solution (1% BSA, 0.5% FBS, 0.1% Tween in PBS) was added for 30 min at room 160 
temperature (RT). It was replaced by 100 µl/well of anti measles N-protein monoclonal 161 
antibody (mouse, Chemicon mAb 8906 or ECACC 95040312) diluted 1:500 in blocking 162 
solution for 30 min at RT. Wells were washed twice with blocking solution and incubated for 163 
30 min at RT with 100 µl HRP-conjugate (1:1000 in PBS) and subsequently washed twice 164 
with 500 µl blocking buffer. Five min after the addition of 100 µl MB Blue POD, the wells 165 
were rinsed with water. Plaques were counted by eye or under the microscope. Titres were 166 
calculated with the formula 0.5(axb/c+dxb/e)=50% plaque reduction titre according to Ho and 167 
Babiuk (13). Plaque reduction titres of ≥1:8 were considered positive.  168 
 169 



































































 3.1. Seroprevalence of measles antibodies  171 
 3.1.1 Seronegativity and WHO target 172 
Figure 1 shows the percentages of children who displayed a negative or equivocal measles 173 
IgG antibody titre by age. This analysis included 13,977 children aged 1-17 year regardless of 174 
the presence of a vaccination card. 175 
The overall prevalence of seronegativity in children tested for measles IgG aged 1 to 17 years 176 
was 10.0% (95% CI 9.4-10.7). In addition, 2.3% (95% CI 2.0-2.7) of children displayed an 177 
equivocal titre. In 2-4 year old children, the prevalence of seronegativity was, on average, 178 
10.0% (95% CI 8.7-11.6). Each age stratum within this age group met the WHO target for 179 
seronegativity (<15%). The prevalence of seronegativity in 5-9 year old children was, on 180 
average, 8.4% (95% CI 7.4-9.5). Also in this group each age stratum was below the respective 181 
WHO target for seronegativity (<10%). The prevalence of seronegativity in 10-17 year old 182 
children and adolescents was, on average, 8.3% (95% CI 7.6-9.1). In contrast to the younger 183 
age groups, each age stratum missed the WHO target for 10 to 19 year olds of 5%. The overall 184 
prevalence of an equivocal titre level in children aged 1 to 17 years was 2.3% (95% CI 2.0-185 
2.7). Low titres in vaccinated persons can be a consequence of waning immunity (secondary 186 
vaccine failure) or insufficient response to the vaccine (primary vaccine failure). Prevalence of 187 
equivocal titres was higher in older children: in 2 to 4 year olds, only 0.8% (95% CI 0.5-1.4) 188 
had equivocal titres, whereas in 5 to 9 year olds and in 10 to 17 year olds, the proportion was 189 
1.65% (95% CI 1.3-2.1) and 3.3% (95% CI 2.8-3.9), respectively.  190 
>Figure 1: Seronegativity and equivocal IgG Titre for Measles by age< 191 
 3.1.2 Seronegativity and documentation of vaccination 192 
Figure 2 shows the proportion of seronegativity in children for whom a vaccination card was 193 
provided (or for whom parents reported that they were (yet) unvaccinated) in comparison to 194 
children for whom parents did not present a vaccination card at the study centre or for whom 195 
the vaccination card was reported to be incomplete. In children aged 1-17 years the proportion 196 
of seronegative children was significantly higher in children without a vaccination card 197 
(16.0%; 95% CI 13.4-19.1) than in children with a valid vaccination card (9.5%; 95% CI 8.9-198 
10.2). Prevalence of seronegativity was especially high in children aged 2-4 and 5-9 years 199 



































































respectively). No difference was seen among the one year old children; however, in this age 201 
group, vaccination cards were unavailable only for 6 children.  202 
 203 
 >Figure 2: Measles seronegativity by age and by availability of vaccination card< 204 
 205 
 3.1.3 Positive and negative predictive value of parental reports on natural measles 206 
infection 207 
Our study comprised a subgroup of 743 unvaccinated children for whom antibody testing was 208 
performed and whose parents had reported whether or not their child had a history of measles. 209 
In this subgroup were 220 unvaccinated children with positive or equivocal measles antibody 210 
titres, 98 of whom were reported to have had measles. The positive predictive value (PPN) for 211 
parental reported history of measles infection was 0.79 (Table 1). Of the 613 unvaccinated 212 
children whose parents did report no measles infection, 122 children had positive or equivocal 213 
measles titre values. We calculated the overall negative predictive value (NPV) to be 0.81. 214 
However, clear differences were detected by age (Table 1). PPV was 0.00 (NPV 0.99) in 215 
children aged 1 year, 0.00 (NPV 0.82) in children aged 2-4 years, 0.62 (NPV 0.81) in children 216 
aged 5-9 years, 0.75 (NPV 0.72) in children aged 10-13 years and 0.89 (NPV 0.53) in children 217 
aged 14- to 17 years. 218 
>Table 1 < 219 
 3.1.4 Seroprevalence and socio-demographic and vaccination status related 220 
factors 221 
Table 2 shows the percentages of children who were measles IgG seronegative, equivocal or 222 
seropositive by different sociodemographic and vaccination status related factors. The 223 
following analyses include only those 13,017 children for whom a vaccination card was 224 
presented or for whom it was reported that they were (yet) unvaccinated. 225 
The overall prevalence of seronegativity in children aged 1 to 17 years was 9.5% (95% CI 226 
8.9-10.2); 2.3% (95% CI 2.0-2.6) of children displayed an equivocal titre level. The 227 
proportion of seronegative children differed by age and was highest in children aged 1 year 228 
(39.2%; 95% CI 34.2-44.5) and lowest in children aged 5 to 17 years (7.7%). The proportion 229 
of children with equivocal titre level was higher in children older than 10 years than in 230 



































































residence. Differences were also obvious regarding maternal education level with a high 232 
proportion of seronegativity in children of highly educated mothers and a lower proportion in 233 
children of mothers with a low education level. A high proportion of immigrated children was 234 
seronegative (14.5%; 95% CI 10.9-19.1) whereas the prevalence of seronegativity was slightly 235 
lower in children with migration background who were born in Germany (8.2%; 95% CI 6.9-236 
9.8) and in children without a migration background (9.5%; 95% CI 8.9-10.3). Also the 237 
proportion of children with equivocal antibody levels was higher among immigrants.  238 
Seroprevalence differed most by vaccination status. Seronegativity was 68.8% (95% CI 65.2-239 
72.2) in unvaccinated children, 6.5% (95% CI 5.4-7.8) in children who had received a single 240 
dose vaccination and 4.3% (95% CI 3.8-4.9) in children who had received (at least) two 241 
vaccination doses. Seroprevalence differed not only by the number of vaccine doses received 242 
but also by the time since last vaccination and also by the age of the vaccinee at which the first 243 
dose was received. We determined differences by the time since last vaccination stratified 244 
accordingly to the number of vaccine doses. In children who had received a two-dose 245 
vaccination the prevalence of seronegativity was higher in children who had received their last 246 
vaccination 3 to 6 years before the study (4.5%; 95% CI 3.8-5.3) and more than six years 247 
before the study (8.4%; 95% CI 7.0-10.1) in comparison to children who had received their 248 
last vaccination less than two years before the study (2.7%; 95% CI 2.1-3.4). Corresponding, 249 
the proportion of children with equivocal titres was higher the longer the time period since last 250 
vaccination had been.  251 
Seroprevalence was also lower in children who had received the first measles vaccination 252 
during their first year of life in comparison to children who had received it later. Interestingly, 253 
age-related differences at first measles vaccination were also seen within the group of children 254 
who had received a second vaccination: 8.9% (95% CI 6.7-11.7) of children who had received 255 
their first vaccination during their first year of life were seronegative in comparison to 4.0% 256 
(95% CI 3.5-4.6) of children who received the first vaccination after their first year of life. 257 
Antibody levels were also more often equivocal in children who had received their first 258 
vaccination at an early age. We observed a linear association between age up to the 17 months 259 
at first vaccination and seronegativity in children who had received two measles vaccinations, 260 
had their last vaccination no more than six years before the study and had no history of 261 
measles infection (Figure 3).  262 



































































In the whole study population, seronegativity was slightly lower in children for whom parents 264 
reported a history of measles (8.0%; 95% CI 6.1-10.4) in comparison to children without a 265 
reported history of measles (9.9%; 95% CI 9.2-10.6). However, significant differences were 266 
only found within the group of unvaccinated children: 81.4% (95% CI 77.4-84.8) of children 267 
without a history of measles infection were seronegative, whereas only 21.3% (95% CI 14.5-268 
30.1) of children whose parents reported a measles history were seronegative. Interestingly, 269 
also only 25.9% (95% CI 12.4-46.2) of children whose parents were unsure whether their 270 
child had had measles were seronegative. 271 
 272 
 3.1.5 Seroprevalence of neutralising measles antibodies  273 
To investigate vaccinated study subjects who showed a negative measles virus antibody value 274 
in the ELISA test, several sera were investigated for presence of neutralizing antibodies with 275 
the Focus Reduction Neutralisation Test (FRNT). Sera of 30 adolescents above the age of 14 276 
who had IgG antibody titres below 150 mIU/ml, had their last vaccination more than nine 277 
years before the study and had no history of measles were tested by FRNT. Only one out of 30 278 
sera was tested seronegative by FRNT. In the remaining 29 sera, antibodies were detected 279 
(1:20-1:274). In 27 of them antibodies were only detectable if dilution was below 1:120. 280 
We also re-analysed 20 sera from children who had received their first vaccination before the 281 
age of one year and had received at least two doses of measles vaccine, with the last dose less 282 
than three years before the study. These 20 children had IgG measles antibody titres between 283 
4 and 144 mIU/ml in the ELISA test. Also in this group measles antibodies were detectable by 284 
FRNT in all but one child if dilution did not exceed 1:120.  285 
As a control, 25 sera of unvaccinated children aged below 7 years who had an IgG measles 286 
antibody titre of 0-77 mIU/ml in the ELISA test were tested by FRNT. The FRNT titre was 287 
negative (<1:8) in all of them. 288 
 289 
 3.1.6. Factors associated with missing measles seroprevalence in vaccinated 290 
children  291 
Considering that measles vaccination is the most important factor associated with 292 
seroprevalence of measles antibody titres, we performed detailed uni- and multivariate 293 



































































modifying the odds of a negative antibody titre after vaccination (Table 3). These analyses 295 
included 12,161 vaccinated children whose blood sample was taken at least 21 days after their 296 
first vaccination. 297 
In addition to the variable of parental reported measles infection, factors that were tested 298 
statistically significant in the univariate analysis were included in the multivariate analysis. 299 
The analysis stratified for single dose or two-dose vaccination schedules indicated that 300 
seronegativity was associated with the number of years that had passed since last vaccination: 301 
Children who had received their last vaccination more three to six years before the study had a 302 
two- to three-fold odds of being seronegative in comparison to children who had received the 303 
last (of at least two) vaccination no more than two years before the study (OR 1.95; 95% CI 304 
1.37-2.77). Children who had received their last vaccination more than six years before the 305 
study had a three-fold odds of being seronegative in comparison to children who had received 306 
their last vaccination no more than two years before the study (OR 3.67; 95% CI 2.37-5.69).  307 
Seronegativity was more likely in children who had received the first measles vaccination 308 
during their first year of life than in children who had received the first dose after the first year 309 
of life. The odds of being seronegative after early vaccination was 2.86 (95% CI 1.64-3.19) 310 
for a single dose and was 2.29 (95% CI 1.64-3.19) for two-dose vaccination. 311 
Seronegativity was more likely in children below the age of 2 years (OR 2.38; 95% CI 1.31-312 
4.31) than in children aged 10 to 17 years. Boys were more likely to be seronegative than girls 313 
(OR 1.33; 95% CI 1.10-1.61). Immigrants were more likely to be seronegative than children 314 
without a migration background (OR 2.35; 95% CI 1.50-3.69). On the other side, children of 315 
immigrants born in Germany were less likely to be seronegative (OR 0.59; 95% CI 0.40-0.88). 316 
A low maternal education level was associated with lower odds for seronegativity in 317 
comparison to a medium maternal education level (OR 0.70; 95% CI 0.52-0.95).  318 
In this group of vaccinated children, children whose parents reported a history of measles 319 
were no more likely to be seronegative than children whose parents had not reported a history 320 
of measles. No statistically significant association was found between seronegativity and place 321 





































































4. Discussion 325 
Main results 326 
The prevalence of seronegativity found in our study was below the WHO European Region 327 
targets (1) for measles elimination of <15% in children aged 2 to 4 years and <10% in 5 to 9 328 
year-olds. However, the prevalence of seronegativity in 10 to 17 year-olds seen in our study, 329 
exceeded the WHO European Region target of <5%. The proportion of seronegative children 330 
was particularly high in the youngest children (one year of age), indicating a relevant delay of 331 
the first measles vaccination which is scheduled in Germany at the age of 11 to 14 months.  332 
Seronegativity was lower in children for whom a vaccination card was available compared to 333 
those for whom no vaccination card was provided.  334 
Seronegativity was highest in unvaccinated children and was (slightly) above the overall 335 
WHO target level of 5% in children who had received a single dose vaccination. 336 
Seronegativity was below the target level in children with a two-dose vaccination. Thereby, 337 
this large population based sero-epidemiological study supports and confirms once again the 338 
crucial importance of a two-dose vaccination schedule to achieve the goal of measles 339 
elimination (14-16).  340 
We performed multivariate analyses to investigate which vaccination schedule may be 341 
associated with low antibody titres and which additional determinants may be associated with 342 
an increased risk for seronegativity in the vaccinated German population. Our data may serve 343 
as valuable information to public health decision makers to adapt vaccination schedules in 344 
order to minimise the time period of susceptibility, the risk for measles infection for 345 
individuals amenable to vaccines and the risk and size of measles outbreaks overall. 346 
Multivariate analyses showed a three-fold odds of seronegativity in children whose last 347 
vaccination had been more than six years before this study. It is remarkable that even in 348 
children who received a second vaccination after the first year of life, an early first vaccination 349 
was associated with a higher risk of seronegativity. 350 
 351 
Strengths and Limitations 352 
Our sero-epidemiological study was conducted in more than 12,000 children and adolescents 353 



































































based sampling. Our study thereby overcomes the limitation of former seroprevalence studies 355 
and can be considered representative for German children and adolescents.  356 
Vaccination status was obtained directly by the vaccination records (vaccination card). By 357 
using vaccination cards, validity of the date of vaccination and the administered type of 358 
vaccine was high and unaffected by recall problems. This allowed us to identify real 359 
vaccination failure rates. However, we can not be sure that every vaccination had been 360 
documented in the provided vaccination card. Although we excluded children from our 361 
analyses whose vaccination cards were reported to be incomplete, completeness could not be 362 
systematically ensured. Possible determinants of vaccination success (age at first vaccination, 363 
time since last vaccination, one- or two dose vaccination schedule, place of vaccination 364 
(abroad or Germany) and ethnic origin) varied considerably. This enabled us to identify 365 
populations with a higher proportion of seronegative children and to investigate which 366 
determinants may substantially alter the success of vaccination.  367 
In a study of this size, measles IgG antibodies must be measured by an automated ELISA 368 
procedure. Since ELISA has a lower sensitivity compared to PRNT, which is considered as 369 
the gold standard for determining measles-neutralising serum antibodies (17), seronegative 370 
children are not necessarily susceptible to measles. This relevant limitation was overcome by 371 
re-testing seronegative subgroups (young age at first vaccination, adolescents suspected to be 372 
subject to relevant waning effects) for plaque reduction capacity by FRNT.  373 
ELISA and FRNT cannot differentiate between immunity after vaccination and natural 374 
immunity. Since natural infection with measles virus results in a higher titre than the 375 
vaccination (18-21), undetected measles wild virus contact may have confounded the study. 376 
We tried to minimise this confounding possibility by asking the parents about any clinical 377 
history of measles by a standardised interview performed by a physician. Since measles has a 378 
very uniform course and subclinical cases are seen only after reinfection or in vaccinees with 379 
waning immunity, parents will usually remember a previous primary measles infection and 380 
recall bias seems rather unlikely. On the other hand, other rash-fever diseases caused by 381 
rubella virus, parvovirus B19 or streptococci may be misdiagnosed as measles if a laboratory 382 
based diagnosis is not performed. Data on validity of parent reported infectious disease history 383 
are limited and mainly relate to varicella (22). The validity of parent reported information is 384 
supported by the fact that the estimated geometric mean titre (GMT) was considerably higher 385 



































































children with vaccine-induced measles antibodies (data not shown). In a subgroup of 743 387 
unvaccinated children whose parents reported whether or not the child had had measles, we 388 
estimated the positive and negative predictive values of this parental reported history with 389 
lower NPV in adolescents and lower PPV in young children (table 1). Thus, the probabilities 390 
of both, unreported wild virus contact and of undocumented vaccination increase with age. 391 
These phenomena may have confounded our results. 392 
 393 
Waning 394 
Our study clearly showed that seronegativity increases as time since last vaccination passes. 395 
This waning of antibody level was seen in children with a single dose vaccination and also in 396 
children with a two dose vaccination schedule and has been shown in many previous studies 397 
(14, 23-30).  398 
In contrast to the results from (14) who showed a longer half life of seropositivity after two-399 
dose vaccination, we found no such difference three years after the last vaccination between 400 
children who had received a single vaccination and children who had received a two-dose 401 
vaccination. However, the proportion of seronegativity was lower after the two-dose 402 
vaccination schedule than after the single-dose schedule. We cannot exclude than any small 403 
difference in the decay rate may have went unnoticed as we grouped the time since last 404 
vaccination into only three categories (0-2; 3-6 and >6 years since last vaccination) in order to 405 
obtain a meaningful size of each stratum for our multivariate analyses.  406 
This study allows for an assessment of the waning effects that occur in a population with a 407 
vaccination coverage of almost 95% for at least one dose of measles vaccine (31, 32). We 408 
used the most conservative cut-off point of 150 mIU/ml for protective antibodies against 409 
measles disease in our study and excluded equivocal levels (150 – 350 mIU/ml). Since it has 410 
been demonstrated that vaccinees with an equivocal or even negative titre might nevertheless 411 
be protected (33), one cannot conclude that all of these children are susceptible to measles 412 
infection.  413 
It is widely agreed that the PRNT correlates best with protection (34-38) and it is known that 414 
ELISA sensitivity is low especially for samples containing low concentrations of neutralising 415 
antibody (17, 39, 40). Clinical sero-epidemiological analyses using PRNT studying protective 416 
antibody titres in outbreaks indicate that a cut-off of 0.2 IU/ml suggests protection. However, 417 



































































transmit the virus, thereby contributing to enduring circulation and failure of the elimination 419 
goal (35, 41, 42).  420 
Unfortunately, plaque neutralisation tests are costly and labor-intensive. It was therefore not 421 
possible to test all sera by PRNT. We did however re-analyse sera of 30 vaccinated 422 
adolescents by FRNT who had been tested seronegative by ELISA in order to allow for a 423 
better assessment of the susceptibility in children. In 29 of these adolescents, antibodies could 424 
be detected in the FRNT. Since FRNT and PRNT use the same test principle and FRNT 425 
differs only by the method of detection, it can be assumed that the results of the FRNT are 426 
comparable to the PRNT. Nevertheless, it remains questionable if the antibody levels in these 427 
adolescents can be considered fully protective (42).    428 
 429 
Age at first vaccination 430 
A number of investigations have shown that immunisation against measles at a very early age 431 
is associated with an impaired immune response (23, 43-52). However, data on immune 432 
response failure to the second measles vaccination (after an early first vaccination) are not 433 
fully conclusive, even if the second vaccination is given in the second year of life or even 434 
later. Several studies showed that the immune response to revaccination at an older age was 435 
impaired in children who were vaccinated at an early age (43, 51, 53, 54). These results were 436 
confirmed by Stetler (55). However, in contrast to the results from Black (53), neutralising 437 
antibody tests showed that most children with an impaired immune response after 438 
revaccination were successfully primed and probably also protected (55). Two other studies 439 
(44, 48) found no impaired response to the secondary vaccination in children with an early 440 
first dose.  441 
Our study shows that young age at first vaccination is associated with a higher probability of 442 
seronegativity, even in children that were revaccinated at an older age (Table 3, Figure 3). 443 
These results indicate that mispriming of the immune system after early vaccination cannot be 444 
cured by a late second dose of MCV. This finding is alarming, but must be weighed against 445 
the benefit for the total population of a shorter window of susceptibility (54, 55). Further 446 
detailed analyses are therefore necessary. The assessment of the possible effects of early 447 
measles vaccination should also take into account work on the age-dependent humoral and 448 



































































equivalent to susceptibility. Especially in young children no correlation between titres 450 
measured by PRNT and the IgG response measured by ELISA was seen (57).  451 
To assess whether early vaccinated children may be protected despite a negative ELISA result, 452 
we re-analysed sera of 20 children for neutralising antibodies. The results showed that 19 sera 453 
were tested positive by FRNT. As it was the case in ELISA negative individuals which were 454 
suspected to waning of antibodies with a longer time interval since last vaccination, FRNT 455 
was positive, but titres did not exceed the 1:120 border suggested earlier (42). Therefore, 456 
neutralising antibodies were detected, but protectivity remains questionable.  457 
 458 
Interindividual variations in seronegativity by age, gender and race 459 
The proportion of seronegative children was highest in the youngest age group and the 460 
proportion of an equivocal titre level was highest among adolescents. We identified two main 461 
associated factors: a high proportion of (yet) unvaccinated young children and a longer 462 
average time period since last vaccination in older children and thus presumably waning titres. 463 
However, the odd of being seronegative was higher in the youngest vaccinated children even 464 
after controlling for the number of vaccinations, age at first vaccination, years having passed 465 
since last vaccination, parent’s reported history of a measles infection and other potentially 466 
confounding variables (Table 3). Taking into account that the NPV for parental reported 467 
measles is lower in adolescents than in young children, it seems plausible that the higher 468 
proportion of seronegativity in young children is due to more frequent wild virus measles 469 
contact that goes unnoticed by parents in older children and adolescents. In addition, 470 
incomplete documentation of vaccination is more likely in older children.  471 
In our study multivariate analyses showed a higher odds of being seronegative in boys than in 472 
girls. This result is in line with investigations on sex differences in the humoral antibody 473 
response to live measles vaccine in young adults (58), with investigations on sex differences 474 
of vaccine efficacy (59), with investigations on sex specific mortality ratios between medium 475 
and high titre measles vaccines (60) and with reports of gender specific rates of adverse events 476 
after MMR vaccination (61). The mechanisms underlying these gender differences are not 477 
completely understood. However, immune responses in general are known to differ by gender 478 
and the genetic control of immunoglobulins have been shown to be associated with the X 479 
chromosome (62). An additional contributing factor to a more favourable seroconversion rate 480 



































































maternal antibodies are assumed to decrease seroconversion rate after vaccination, early 482 
vaccinations of girls may lead to higher seroconversion rate than in boys. 483 
Immigrant children are at particular risk of incomplete immunisation (7, 64-68). In addition, 484 
previous studies support that differences in seronegativity may arise not only from different 485 
vaccination coverage but also from genetic factors (69-81). These may be involved in the 486 
variation in immune response to measles vaccine in different populations. In our study 487 
differences in seronegativity were detected between German-born and foreign-born immigrant 488 
children. A possible explanation or contributing fact for this observation may be lower quality 489 
of measles vaccine used in other countries, or environmental factors influencing measles 490 
vaccine efficacy such as interruption of the cold chain. Inappropriate vaccine storage as a 491 
reason for poor vaccine efficacy is supported by data from Latvia which show that MMR 492 
vaccine coverage estimates agree with the observed rubella seroprofiles but not with the 493 
measles vaccination coverage data. In addition, discrepancies between documented vaccine 494 
coverage and seroprevalence data are known from the WHO European Seroepidemiology 495 
Network (ESEN2) for Bulgaria, Latvia and Romania (82). Although the data base for our 496 
study relied on individual medical records, the quality of foreign vaccination cards may differ 497 
from the German documentation in some cases and may have contributed to overestimation of 498 
vaccine coverage in immigrant children.  499 
 500 
5. Conclusions 501 
The prevalence of seronegativity in the German population was below the WHO targets for 502 
measles elimination in children aged 2 to 9 year-olds but exceeded the target for 10 to 17 year-503 
olds. Age differences in the level of seronegativity were found to be mainly due to differences 504 
in vaccination coverage. However, immigrant children were more often seronegative even if 505 
vaccination(s) had been documented. Further increase of the two-dose vaccination coverage is 506 
necessary in order to achieve the WHO targets. Catch up vaccination campaigns should focus 507 
on adolescents and immigrants.  508 
Our large, representative study showed inferior immune responses in children who were very 509 
young age at first vaccination (even if a second vaccination was given at older age). Children 510 
who received their first vaccination within the first 12 months of life exceeded the target of 511 



































































waning of antibodies with increasing time since the last vaccination. The prevalence of 513 
seronegativity exceeded the WHO target of less than 5% in those children whose last 514 
vaccination dose (single dose or two-dose vaccination) was older than six years.  515 
The protective effect of measles antibodies below the cut-off of 150 mIU/ml in vaccinated 516 
subjects needs to be investigated further.  517 
Our results may contribute to discussions about future adaptations to the current vaccination 518 
schedules. Protecting the majority of children at an early age by scheduling the first 519 
vaccination within the first year of life has to be traded off against the lower prevalence of 520 
seropositivity, especially as failure of the first vaccination cannot be compensated by a second 521 
vaccination in a significant proportion of children. This risk assessment will be highly 522 
influenced by the measles incidence of a given region. Since measles incidence is still high in 523 
Germany, for the time being, reducing the vulnerable time period through early vaccination 524 
far outweigh the risk of being seronegative after an early vaccination. 525 
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Seroprevalence of measles lgG titre in unvaccinated children with and without a history of measles 
infection by age
Titre negative



















150-350mIU/ml*    
(95% CI)
Titre positive 
>350mIU/ml*    
(95% CI)
Total 13,017 9.5% (8,9-10.2) 2.3% (2.0-2.6) 88.2% (87.5-88.9)
Gender
male 6,668 10.2% (9.3-11.1) 2.3% (1.9-2.8) 87.6% (86.6-88.5)
female 6,349 8.8% (8.1-9.6) 2.3% (1.9-2.7) 88.9 (88.0-89.7)
age (years)    
1 456 39.2% (34.2-44.5) 0.9% (0.3-3.0) 59.9 (54.3-65.1)
2-4 1,894 9.6% (8.2-11.1) 0.8% (0.4-1.3) 89.7% (88.1-91,1)
5-9 4,082 7.7% (6.6-8.8) 1.7% (1.3-2.2) 90,7% (89.4-91,8)
10-17 6,585 7.7% (7.0-8.5) 3.2% (2.7-3.8) 89.1% (88.1-89.9)
place of residence    
former East 4,522 7,8% (6.9-8.7) 2.8% (2.2-3.6) 89.4% (88.4-90.4)
former West 8,495 9,9% (9.2-10.6) 2.2% (1.8-2.6) 87.9% (87.1-88.7)
migration background (one sided and two sided)    
German-born 2,053 8.2% (6.9-9.8) 1.0% (0.6-1.6) 90.8% (89.1-92.2)
foreign-born 383 14.5% (10,9-19.1) 8.0% (5.4-11.6) 77.5% (72.5-81.9)
no migration background 10,427 9.5% (8,9-10.3) 2.4% (2.0-2.8) 88.1% (87.3-88.9)
Maternal education level    
high 3,61 11.2% (10.1-12.4) 2.3% (1.7-3.0) 86.5% (85.1-87.8)
medium 6,09 9.4% (8.5-10.4) 2.4% (2.0-2.9) 88.2% (87.1-88.2)
low 2,741 8.0% (7.0-9.2) 2.0% (1.5-2.7) 90.0% (88.6-91.2)
vaccination status    
unvaccinated 827 68.8% (65.2-72.2) 0.8% (0.4-1.6) 30.4% (27.1-34.0)
single dose vaccination 2,467 6.5% (5.4-7.8) 2.4% (1.7-3.2) 91.1% (89.6-92.5)
two-dose (or more) vaccination 9,723 4.3% (3.8-4.9) 2.4% (2.0-2.8) 93.3% (92.6-93.9)
years since last vaccination    
one dose    
years since last vaccination 0-2 798 6.7% (4.8-9.1) 1.4% (0.7-2.8) 91.9% (89.0-94.1)
years since last vaccination 3-6 679 6.0% (4.0-8.9) 1.4% (0.8-2.7) 92.6% (89.5-94.8)
years since last vaccination >6 972 6.9% (5.3-8.9) 3.7% (2.5-5.5) 89.4% (87.0-91.4)
two (or more) doses    
years since last vaccination 0-2 4,192 2.7% (2.1-3.4) 1.4% (1.0-1.8) 96.0% (95.2-96.6)
years since last vaccination 3-6 4,154 4.5% (3.8-5.3) 2.9% (2.3-3.6) 92.6% (91.7-93.5)
years since last vaccination >6 1,373 8.4% (7.0-10.1) 4.1% (3.1-5.5) 87.4% (85.3-89.3)
age at first measles vaccination    
one dose    
first dose aged 0-11 months 80 14.4% (7.4-26.4) 1.8% (0.4-7.4) 83.8% (71.9-91.3)
first dose aged 1-17 years 2,369 6.3% (5.2-7.7) 2.4% (1.7-3.3) 91.3% (89.7-92.7)
two (or more) doses    
first dose aged 0-11 months 656 8.9% (6.7-11.7) 3.5% (2.2-5.6) 87.6% (84.7-90.0)
first dose aged 1-17 years 8,958 4.0% (3.5-4.6) 2.3% (2.0-2.7) 93.7% (93.0-94.3)
history of measles infection    
no 10,787 9.9% (9.2-10.6) 2.3% (1.9-2.7) 87.9% (87.1-88.7)
yes 772 8.0% (6.1-10.4) 2.0% (1.1-3.4) 90.1% (87.2-92.3)
Don't know 478 6.6% (4.6-9.3) 2.3%(1.2-4.2) 91.1% (87.8-93.6)
unvaccinated    
no 613 81.4% (77.4-84.8) 0,6% (0,2-1,5) 18.0% (14.6-22.0)
yes 130 21.3% (14.5-30.1) 0,0% 78.7% (69.9-85.5)
Don't know 771 25.9% (12.4-46.2) 3.5%(0.5-21.4) 70.6% (50.2-85.2)
vaccinated    
no 10,174 4.8% (4.2-5.4) 2.4% (2.0-2.8) 92.9% (92.1-93.5)
yes 642 5.0% (3.5-7.2) 2.4% (1.4-4.2) 92.6% (89.8-94.6)
Don't know 450 5.0% (3.3-7.6) 2.2% (1.1-4.2) 92.8% (89.3-95.2)
Seroprevalence of measles lgG titre in children with documentation of vaccinations by socio-demografic 





(95 % CI) p Value
multivariate OR* 
(95 % CI) p Value
Gender 0.015 0.004
male 1.33 (1.10-1.60) 1.33 (1.10-1.61)
female Referent Referent
age (years) <0.001 0.024
1 1.31 (0.80-2.16) 2.38 (1.31-4.31)
2-4 0.52 (0.36-0.75) 1.09 (0.65-1.83)
5-9 0.64 (0.49-0.82) 0.99 (0.74-1.34)
10-17 Referent Referent
place of residence 0.78
former East Referent
former West 1.03 (0.82-1.30)
migration background (one sided and two sided) <0.001 <0.001
German-born 0.52 (0.37-0.73) 0.59 (0.40-0.88)
foreign-born 2.48 (1.68-3.66) 2.35 (1.50-3.69)
no migration background Referent Referent
Maternal education level 0.038 0.06
high 0.82 (0.64-1.06) 0.83 (0.64-1.08)
medium Referent Referent
low 0.71 (0.54-0.93) 0.70 (0.52-0.95)
years since last vaccination
one dose <0.001 <0.001
years since last vaccination 0-2 1.71 (1.08-2.70) 1.39 (0.85-2.28)
years since last vaccination 3-6 2.31 (1.43-3.72) 2.92 (1.74-4.89)
years since last vaccination >6 2.70 (1.89-3.85) 3.05 (1.88-4.93)
two (or more) doses
years since last vaccination 0-2 Referent Referent
years since last vaccination 3-6 1.70 (1.33-2.18) 1.95 (1.37-2.77)
years since last vaccination >6 3.35 (2.43-4.62) 3.67 (2.37-5.69)
age at first measles vaccination <0.001 <0.001
one dose
age at first dose  <12 months 4.03 (1.86-8.74) 2.86 (1.18-7.00)
age at first dose  >11 months 1.41 (1.09-1.83) 1.00 (1.00-1.00)
two (or more) doses
age at first dose  <12 months 2.33 (1.66-3.26) 2.29 (1.64-3.19)
age at first dose  >11 months Referent Referent
history of measles infection 0.848 0.973
no 0.90 (0.61-1.35) 0.95 (0.63-1.44)
yes Referent Referent
Don't know 0.99 (5.90-1.68) 0.98-0.56-1.74)
Uni- and Multivariate odds ratios (OR) for the association between sociodemographic and medical 
variables, vaccination status  and the risk of negative measles antibody titres (IgG <150 mIU/ml) in 
vaccinated children
* Adjusted for gender, age, migration background, maternal education level, years since last measles 
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Figure 2  
Measles seronegativity by age and by availability of vaccination card 
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Seronegativity by age at first vaccination dose (n=7001, age 1-17, at least two doses measles 
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* Statistically significant p<0.05; t-test; reference: age at first dose > 23 months 
